Raffi Calikyan, MD
Pulmonary Disease · Bristol, RINPI 1417063603
Payments from drug & device makers
Across 596 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Mylan Specialty L.p.$742
- Boehringer Ingelheim$741
- Sanofi$726
- Regeneron Healthcare Solutions, Inc.$584
- plus $5K from 54 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,434 in reported general payments places this provider in the 80th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Bristol
- Elias JabbourWarwick$13.2M
- James KlingerRiverside$2.7M
- Ronald GilmanRiverside$352K
- Michael StanchinaEast Greenwich$219K
- William CorraoWarwick$166K
- Corey VentetuoloRiverside$51K
- John LadettoRiverside$39K
- Christopher MullinProvidence$19K
- Rachel DarlingProvidence$13K
- Rabih El BizriProvidence$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.